Full Press Release Details
Zynex Declares Special Cash Dividend of $0.10
Per Share and 10% Stock Dividend
CO - November 10, 2021 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture
and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics,
today announced it has declared a one-time special cash dividend of $0.10 per share and a stock dividend of 10% per share. Both dividends
are on its Common Stock. The dividends are payable to all common stockholders of record as of the close of business on January 6, 2022,
payable on or about January 21, 2022. Based on the current number of shares outstanding the cash dividend is expected to result in an
aggregate distribution of approximately $3.5 million. The stock dividend will result in an issuance of approximately 3.5 million additional
shares of common stock.
Thomas Sandgaard, CEO, Chairman and Founder said: "With our continued
strong financial performance, it is appropriate to reward our shareholders for their support. Returning capital to shareholders reflects
our strong financial position and confidence in our future. Following this dividend, our cash balance remains strong and provides us the
flexibility to expand our business both through acquisitions and organic growth."
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation;
and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a
fluid monitoring system for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.
Safe Harbor Statement
contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform
Forward-looking statements
are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and
many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the
forward-looking statements. Therefore you should not rely on any of these forward looking statements. The
Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of
projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could
cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking
of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater
financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health
insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation
of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in
our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December
31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement
made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
Contact: Zynex, Inc. (800)
Amato And Partners, LLC
Investor Relations Counsel